Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Acalabrutinib Maintenance Following Cellular Therapy for Large B-Cell Lymphoma Patients at Very High Risk for Relapse

NCT05256641 is registered in ClinicalTrials.gov with Jonsson Comprehensive Cancer Center as lead sponsor.

NCT NCT05256641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05256641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Acalabrutinib Maintenance Following Cellular Therapy for Large B-Cell Lymphoma Patients at Very High Risk for Relapse
Lead sponsor
Jonsson Comprehensive Cancer Center
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 23, 2023
Completion date
January 31, 2028
Enrollment
24 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma, high-grade b-cell lymphoma, secondary central nervous system lymphoma, transformed lymphoma